Boston Scientific Corp. closed 0.01% short of its 52-week high of $101.65, which the company reached on January 22nd.

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...

Boston Scientific Corp (BSX) stock saw a decline, ending the day at $100.31 which represents a decrease of $-0.60 or -0.59% from the prior close of $100.91. The stock opened at $100.91 and touched a ...

Boston Scientific (BSX) closed the most recent trading day at $101.64, moving +1.33% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.53% for the day.

Boston Scientific outperforms competitors with strong growth in atrial fibrillation devices and recent acquisitions. Learn ...

We recently published a list of 10 Hottest Mega-Cap Stocks So Far in 2025. In this article, we are going to take a look at ...

Barclays raised the firm’s price target on Boston Scientific (BSX) to $111 from $86 and keeps an Overweight rating on the shares. The firm says ...

Results from the single-arm trial saw 63.5% of patients able to avoid the symptoms of Atrial fibrillation over the course of ...

Boston Scientific (NYSE: BSX) today reported data from separate studies backing its Farapulse and Watchman FLX systems.

Boston Scientific Corp. is paying $443 million upfront, plus up to $221 million in possible milestones, to buy the remainder ...

Boston Scientific Corp (BSX) stock saw a modest uptick, ending the day at $98.66 which represents a slight increase of $0.49 or 0.50% from the prior close of $98.17. The stock opened at $97.93 and ...

In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Boston Scientific (BSX – Research Report). The ...